MedTrace Logo

A Multicenter Study to Evaluate a Risk-adapted Strategy for Treatment of Extra Cranial Non Seminomateous Malignant Germ Cell Tumour in Children and Adolescent

NCT02104986 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 117

Last updated 2022-08-29

No results posted yet for this study

Summary

The main objective is to assess the benefit-risk ratio of a risk-adapted strategy for treatment of extra cranial NSMGCT in children and adolescent.

Conditions

  • Extra Cranial Non Seminomateous Malignant Germ Cell Tumour

Interventions

DRUG

Velbe-Bleomycin-Cisplatin

Limitation of the number of chemotherapy courses (≤ 4) after the achievement of a clinical and biological response in NSMGCT patients treated with cisplatin-based chemotherapy, in order to reduce treatment long-term effects

DRUG

Vepeside-ifosfamide-Cisplatin

Sponsors & Collaborators

  • Centre Leon Berard

    lead OTHER

Principal Investigators

  • Cécile CONTER, MD · Centre Léon Bérard, Lyon, FRANCE

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-05-12
Primary Completion
2021-10-14
Completion
2021-10-14

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02104986 on ClinicalTrials.gov